Hirsutism future or investigational therapies: Difference between revisions
| Line 8: | Line 8: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
A new topical antiandrogen Fluridil (2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-3-(2,2,2-trifluoroacetylamino)ropanamide) has been developed for hyperandrogenic skin syndromes.[28] Based on these results, a study was conducted as an orientational three-month pilot study to evaluate the efficacy and safety of 2% fluridil gel in female patients with idiopathic hirsutism. The present clinical study has shown that a 2% fluridil gel is a safe and effective treatment method of hirsutism. However, this preparation is not available yet. Compared to systemic administration of antiandrogens, topical fluridil does not affect general health and sexual functions and, more importantly, does not decrease libido.<ref name=" | A new topical antiandrogen Fluridil (2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-3-(2,2,2-trifluoroacetylamino)ropanamide) has been developed for hyperandrogenic skin syndromes.[28] Based on these results, a study was conducted as an orientational three-month pilot study to evaluate the efficacy and safety of 2% fluridil gel in female patients with idiopathic hirsutism. The present clinical study has shown that a 2% fluridil gel is a safe and effective treatment method of hirsutism. However, this preparation is not available yet. Compared to systemic administration of antiandrogens, topical fluridil does not affect general health and sexual functions and, more importantly, does not decrease libido.<ref name="pmid2856356">{{cite journal |vauthors=Wee S, Neilands JB, Bittner ML, Hemming BC, Haymore BL, Seetharam R |title=Expression, isolation and properties of Fur (ferric uptake regulation) protein of Escherichia coli K 12 |journal=Biol Met |volume=1 |issue=1 |pages=62–8 |year=1988 |pmid=2856356 |doi= |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 17:11, 15 September 2017
|
Hirsutism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Hirsutism future or investigational therapies On the Web |
|
Directions to Hospitals Treating Hirsutism future or investigational therapies |
|
Risk calculators and risk factors for Hirsutism future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Future or Investigational Therapies
A new topical antiandrogen Fluridil (2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-3-(2,2,2-trifluoroacetylamino)ropanamide) has been developed for hyperandrogenic skin syndromes.[28] Based on these results, a study was conducted as an orientational three-month pilot study to evaluate the efficacy and safety of 2% fluridil gel in female patients with idiopathic hirsutism. The present clinical study has shown that a 2% fluridil gel is a safe and effective treatment method of hirsutism. However, this preparation is not available yet. Compared to systemic administration of antiandrogens, topical fluridil does not affect general health and sexual functions and, more importantly, does not decrease libido.[1]